

Cover Story
Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers